|Inclusion Criteria:||1) Women and men >/=18 years of age willing and able to participate in all AVL-292-003 clinical study directed activities as defined in the protocol.|
2) Willing and able to sign written informed consent.
3) Body weight >/= 50 kg.
4) Confirmed diagnosis of B-NHL (according to World Health Organization [WHO] classification) including CLL/SLL (International Workshop), or WM (Second International Workshop) by investigator assessment: For subjects with DLBCL, submission of a Formalin-Fixed Paraffin Embedded (FFPE) tumor block or 20 unstained slides from a fresh biopsy or an archival specimen of their lymphoma is required. These samples are required for all DLBCL subjects. During screening site must confirm the existence of pathology material. Within 6 weeks the pathology sample must be provided to LabCorp Clinical Trials (as described in the study-specific lab manual). These samples must be submitted even if the subject is already discontinued from the study.
5) (continuation of # 4) The original diagnostic biopsy and/or other diagnostic datasets (eg, cell marker data) will ordinarily suffice. However, current re-biopsy is mandatory in those situations where new clinical features such as marked acceleration of tumor growth or new appearance of severe B symptoms suggest a possibility of histological transformation. -- Subjects with low grade B-NHL, CLL, or WM which has transformed into high grade lymphoma of the diffuse large cell type (Richter's transformation) are eligible to enroll provided they meet all of the other inclusion/exclusion criteria including ECOG PS ≤ 2 and expected 3 month life expectancy. These subjects should enroll as DLBCL.
6) B cell NHL with bi-dimensional measurable disease >/= 2 cm diameter; or CLL with >/= 5000 leukemia cells/mm^3: CD5+; CD19+; CD20 dim; CD23+; sIg dim; CD79b dim; or WM with monoclonal serum IgM >/= 2x ULN and lymphoplasmacytic marrow cell infiltrate: sIgM+; CD19+; CD20+; CD22+; CD79+. --CLL Subjects: Variations of the intensity of expression of these lymphocyte surface markers may exist and do not prevent inclusion of subject in clinical trial. Ex: CD23 may be variably positive. If CD23 is negative, mantle cell lymphoma (MCL) must be ruled out by negative t(11;14) or absence of cyclin D1 staining by IHC. --WM Subjects: Eligible subjects must meet consensus panel criteria to treat. Some cases of WM may express CD5, CD10, or CD23; care should be taken to differentiate from CLL and MCL. --MCL Subjects: MCL are typically CD5+, CD10- and CD23- (not all cases are CD23-); demonstration of overexpression of cyclin D1 or presence of t(11;14)(q13;q32) translocation necessary to support diagnosis
7) Have failed >/= 1 previous treatment for B-NHL/CLL/WM, and have relapsed or refractory disease following last prior treatment. Subjects with diffuse large B cell lymphoma must have failed, refused, be ineligible, or not otherwise appropriate, per the Investigator's judgment, for autologous stem cell transplant.
8) Eastern Cooperative Oncology Group performance status (ECOG PS) of </= 2 and a life expectancy of at least 3 months.
9) All subjects with preserved reproductive potential must agree to practice abstinence or employ contraceptive measures for the duration of treatment and for 4 weeks following final dosing. -- All male subjects are considered to have reproductive potential. -- Female subjects of reproductive potential are those who: 1) are not at least 50 years old and have no menses for 24 consecutive months; or 2) have not been rendered surgically sterile (having undergone hysterectomy and/or bilateral salpingo-oophorectomy). -- Female subjects of reproductive potential must have a negative serum pregnancy test (minimum sensitivity 25IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 7 days of first day of drug dosing.
10) Ability to swallow oral capsules without difficulty.
11) Have an echocardiogram or multigated acquisition scan of the heart demonstrating left ventricular ejection fraction (LVEF) >/= 50% or >/= the institution's lower limit of normal.
12) Has recovered from adverse, toxic effects of prior therapies to Grade </= 1 (NCI-CTCAE v4) except for alopecia and peripheral neuropathy. This requirement will be subordinate to specific clinical and laboratory criteria that are otherwise specifically addressed in these inclusion/exclusion criteria. Peripheral neuropathy must have recovered to </= Grade 2 except for subjects with WM, who may enroll with Grade 3 peripheral neuropathy if due to the underlying WM.
13) Meet the following clinical laboratory requirements: -- Creatinine clearance by Cockcroft-Gault formula of >/= 30 ml/min -- Total bilirubin </= 1.5 x ULN (unless indirect bilirubin is elevated from Gilbert's syndrome or hemolysis) -- AST and ALT </= 3 × ULN.
14) For subjects with NHL and WM: -- Platelet count >/= 50,000/muL, without transfusion for 7 days before the laboratory test -- ANC >/= 1000/muL, with or without chronic granulocyte growth factor support; if requiring chronic granulocyte growth factor support, then the subject must have been on a stable growth factor dose and regimen for at least 3 weeks prior to C1D1 and have an ANC >/= 1000/muL for at least 3 weeks prior to C1D1; growth factor support for ANC is allowed only for subjects whose neutropenia is due to marrow infiltration by the underlying B-NHL or WM; if there is diagnostic uncertainty regarding the cause of the neutropenia, bone marrow examination must be performed. -- Hemoglobin >/= 8 g/dL without transfusion within 7 days before the laboratory test.
15) Subjects enrolling in Part 1 under AVL-292-003 Protocol Amendment 2.0 will be required to undergo lymph node core biopsies while on treatment, if the subject has a safely accessible tumor as determined by the clinical judgment of the investigator. Lymph node core biopsies for subjects enrolling in Part 2 will be covered under an optional separate consent. Subjects must additionally meet the following criteria on the day of the biopsy: Have accessible tumor tissue that is 1) suitable for core needle biopsy (18 gauge or larger) with acceptable clinical risk as judged by the investigator (eg, palpable peripheral lymph node masses); and 2) which is distinct from index lesions to be followed to assess tumor response - A single fresh tissue biopsy to be performed on C1 Day 15, will be required for all subjects enrolling into Part 1 under AVL-292-003 Protocol Amendment 2.0 if the subject has safely accessible nodal tissue as determined in the clinical judgment of the investigator.
16) (continuation of # 15) The fresh tumor tissue core biopsy should be collected as close to 4 hours after the C1D15 dose administration as possible, and in all cases within 2-6 hours from dosing. Safely accessible tissue is generally understood to mean a peripheral lymph node group that is superficial and readily palpable, not closely adjacent to nearby critical structures (eg, arterial vessels, nerves), and is non-ulcerated, non-inflamed, and non-infected. The investigator will make this determination during the screening physical examination and declare whether the subject is to undergo the biopsy procedure. As a condition for enrollment, the subject must consent to the biopsy if declared by the investigator to be suitable for this procedure.
Criteria truncated, please contact Prinicipal Investigator's office for full criteria